ResearcherKurume UniversityActive in the last 2 years
Takuji Torimura
Matched on ORCID iD 0000-0002-4863-4278; OpenAlex author ID A5013194037. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 14
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper
Papers 4
- Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.gastha.2024.04.011↗
- A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Last author DOI 10.1097/md.0000000000026052↗
- Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Last author DOI 10.1007/s00795-019-00218-5↗
- A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. Last author DOI 10.4103/eus.eus_58_17↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yoshinobu Okabe · 4 shared papers, 2018–2024 · strength 0.45
- Paper Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.gastha.2024.04.011↗
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. DOI 10.4103/eus.eus_58_17↗
- Yoshiki Naito · 3 shared papers, 2018–2024 · strength 0.37
- Paper Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.gastha.2024.04.011↗
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. DOI 10.4103/eus.eus_58_17↗
- Takahiko Sakaue · 3 shared papers, 2019–2024 · strength 0.37
- Paper Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.gastha.2024.04.011↗
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic … DOI 10.1007/s00795-019-00218-5↗
- Tomoyuki Ushijima · 3 shared papers, 2018–2021 · strength 0.27
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. DOI 10.4103/eus.eus_58_17↗
- Paper Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic … DOI 10.1007/s00795-019-00218-5↗
- Hironori Koga · 2 shared papers, 2019–2024 · strength 0.25
- Paper Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.gastha.2024.04.011↗
- Paper Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic … DOI 10.1007/s00795-019-00218-5↗
- Masaru Fukahori · 2 shared papers, 2019–2021 · strength 0.20
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic … DOI 10.1007/s00795-019-00218-5↗
- Toru Hisaka · 1 shared paper, 2024 · strength 0.17
- Takumi Kawaguchi · 1 shared paper, 2024 · strength 0.17
- Tõru Nakamura · 1 shared paper, 2024 · strength 0.17
- Keisuke Miwa · 1 shared paper, 2021 · strength 0.12
- Yusuke Ishida · 1 shared paper, 2018 · strength 0.08
- Hiroto Ishikawa · 1 shared paper, 2018 · strength 0.08
- Jun Akiba · 1 shared paper, 2018 · strength 0.08
- Toru Nakamura · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.